2. 1
2
To the extent any statements made in this presentation contain information that is not historical, these statements are
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements
on our current expectations and projections about future events. Our actual results could differ materially from those
discussed in, or implied by, these forward-looking statements.
Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will,"
"may" and other similar expressions. In addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking statements. Forward-looking statements
include, but are not necessarily limited to, risks and uncertainties, including the difficulty of predicting U.S. Food and
Drug Administration and Canadian Therapeutic Products Directorate approvals, acceptance and demand for new
pharmaceutical products, the impact of competitive products and pricing, new product development and launch,
reliance on key strategic alliances, availability of raw materials and finished products, the regulatory environment, tax
rate assumptions, the outcome of legal proceedings, fluctuations in operating results and other risks detailed from
time to time in the Company's filings with the Securities and Exchange Commission and the Ontario Securities
Commission. IntelGenx undertakes no obligation to update or revise any forward-looking statement.
2
Forward Looking Statements
4. 3
2
4
Oral Thin Films
Oral Thin Films Provide
Significant Market Opportunities
for Improving Drug Delivery
• IntelGenx CEO co-developer of the
Listerine breath strips
• Oral films provide quicker action to relieve symptoms
• IntelGenx’s goal to become a leader in
pharmaceutical oral film development &
manufacturing
5. 4
5
Clearly Defined BD Strategy
We are focused on areas where oral films
are particularly well-suited:
Develop and commercialize products that provide tangible patient benefits
leveraging oral films, such as:
• Reduced side effects
• Improved bio-availability
• Response time versus existing drugs
• Lifecycle management
• Repurpose existing drugs for new indications using oral films
• “First-to-file” Generic drugs where high technology barriers to
entry exist in reproducing branded films
6. 6
Prioritization of Future Product Sourcing
Balancing Risks and Opportunities for an Optimized Portfolio
Overall
Risk
Time to MarketSlow Fast
Low
High
Drug Repurposing
Patient Benefits
Lifecycle Mgmt
FTF Generics
IntelGenx Future Focus
Deal Value
Low
Medium
High
7. 6
A Robust Product Pipeline to Address
Significant Market Opportunities
Indication
Partnering
Availability
Formulation
Development
Pilot
Study
Pivotal
Study
Filing Launch
Films Migraine – Rizaport TM -
Rizatriptan
Available
except Spain
Erectile Dysfunction -
Tadalafil
Available
Schizophrenia - Loxapine Available
Central Nervous System -
Montelukast
Available
Respiratory (Cough & Cold) In Discussion
Cardiovascular In Discussion
Opioid Dependence
Par
Pharmaceutical
Undisclosed Term Sheet
Pain Term Sheet
Central Nervous System Term Sheet
5 7
8. 7
8
• High dose version of Wellbutrin XL®
• Only approved, once-daily, bupropion HCl 450mg dose
in a single tablet
• Launched commercially October 2013 in partnership
with Edgemont Pharmaceuticals
• Sold US revenue to SWK Holdings for $6M
• Development cost $2.5M, total revenue $15M = 6-fold
ROI
• Non-dilutive source of funding, will be used to advance
film projects
Successful monetization of first
in-house development
9. 8
9
For Migraines
Leverages VersaFilm™ Technology
• European Mktg Approval – November 2015
• Co-development partnership with RedHill Biopharma
• Definitive agreement signed July 2016 with
Grupo Juste for Spain & additional territories
• Actively pursuing several opportunities to open new
markets - negotiations with future commercialization
partners ongoing
• Planned USA submission to FDA Q1/2017
• Expected USA launch Q3/2017
10. 9
For Erectile Dysfunction
• The first oral thin film using IntelGenx
proprietary drug delivery technology,
VersaFilm™, for ED
• Containing tadalafil (Cialis® - Eli Lilly),
a major molecule in the ED market
• Demonstrated bioequivalence to Cialis®
• Orally disintegrating films without need
for water provide unprecedented patient
convenience and a discrete dosing
alternative
• 505(b)(2) USA NDA submission in
Q1/2017
• Expected USA launch Q1/2018
10
11. 10
For Schizophrenia &
Bipolar 1 Disorder
11
• The first oral thin film using IntelGenx
proprietary drug delivery technology,
VersaFilm™, for Schizophrenia & Bipolar
1 disorder
• Fast-acting loxapine oral dosage – to
treat acute agitation with Schizophrenia &
Bipolar 1 disorder in non-institutionalized
patients
• Reduces risk of pulmonary problems
and potential risk of violence and injury to
patients and others
• Formulation optimization stage – results
expected Q2 2017
12. 11
For Mild Cognitive Impairment
12
• IntelGenx is repurposing Montelukast
for the treatment of MCI by leveraging
its VersaFilm™ technology
• The drug is known and approved for a
completely different indication (asthma)
• Strong preclinical experience
• Results from first phase 1 trial in humans
available
• Looking for a commercial partner
13. 12
2
13
Clinical Data
0.0
100.0
200.0
300.0
400.0
500.0
600.0
0.00 5.00 10.00 15.00 20.00 25.00 30.00
Montelukastconcentration(ng/mL)
Time (hrs)
Montelukast Avg Plasma Profile
Test buccal film 10mg
Ref tablet 10mg
• First clinical study successfully completed
• Significantly increased bioavailability after administration of VersaFilm product
compared to commercial tablet
• Drug crosses blood/brain barrier when given as film
• Phase II-a study (proof of concept) to commence Q1/2017
• First efficacy data in humans available Q4/2017
• Several Pharma companies have expressed strong interest
Before
MMSE 13:
moderate to severe
dementia
MMSE 22:
mild dementia
After 2 Months of
Montelukast
14. 13
14
Completion of Construction
of Manufacturing Facility
• 17,000 sq ft facility in Montreal -
construction completed in Q1 2016
• Facility to be fully operational by Q1 2017
• High capacity manufacturing and
packaging equipment
• Lower costs, controls quality
and de-risks investment
for new products
GROSS MARGINS of 40% PLUS
We have built a state-of-the-art
oral film development and manufacturing facility
15. 14
Strengthened Management Team
Over 20 Employees, including 7 with Ph.D.’s
Andre Godin, CPA, CA
Executive VP, CFO
• 25+ years biotech/pharma
industry experience
• Member of the Canadian
Chartered Professional
Accountants and the
Canadian Institute of
Chartered Accountants
Nadine Paiement, M. Sc.
VP, Research & Development
• Co-inventor of IntelGenx
Trilayer Technology
• 15 years experience in
product development and
technology transfer
Edward Miller, B. Comm
Director, Investor Relations
• 15 years experience in
investor relations
• 10 + years experience in
pharmaceutical / biotech
Horst G. Zerbe, Ph. D.
Chairman, President & CEO
• Co-Founder of Listerine
breath strips
• 30+ years drug delivery /
pharma experience
• Holds over 40 patents in drug
delivery and numerous
scientific publications
15
Dana Matzen, Ph.D.
VP, Business & Corporate
Development
• 15 years experience in
pharmaceutical product
licensing
• Prev. Director, BD at Paladin
• Completed 13 transaction,
7 new product launches
John Durham, B. Sc.
VP, Operations
• 20+ years experience in
pharmaceutical
manufacturing, quality
management, product
development
• Held executive positions with
several Canadian and US
companies
16. 15
16
What Makes IntelGenx the Best in Oral Films
1. History
• Dr. Zerbe a pioneer with over 30 plus years in oral films
2. Formulation Team
• Strong in applying biopharmaceutical aspects to formulation development
• Top quality scientists: highly creative, focused on problem solving & innovative approaches
• Experienced in developing films for oral (GI), sublingual & buccal absorption
3. Clearly Defined Corporate Strategy And Business Model
• Focus on drug repurposing, lifecycle management, patient benefits, and FTF
• Provider of comprehensive pharmaceutical services to industry partners
4. Competitive Manufacturing Capabilities
• First in Canada
• New state-of-the-art manufacturing facility
• Offer one-stop-shopping to our partners with lean operations keeping costs down
• Customized manufacturing equipment
21. 20
21
Solid Platform for Growth
Significant Market Potential
• New manufacturing facility will offer many competitive advantages
• Strengthened management team to accelerate execution of business plan
• Implemented product sourcing strategy to identify high-value product opportunities
• Building strategic partnerships with relevant partners in the pharmaceutical industry
Solid Platform for Growth
